Eyeworld

TAKE A CLOSER LOOK AT THE BENEFITS OF OMIDRIA ® IMPORTANT SAFETY INFORMATION OMIDRIA ® (phenylephrine and ketorolac injection) 1% / 0.3% must be added to irrigation solution prior to intraocular use. OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients. Systemic exposure of phenylephrine may cause elevations in blood pressure. Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other non-steroidal anti-infl ammatories (NSAIDs), or have a past medical history of asthma. The most commonly reported adverse reactions at 2-24% are eye irritation, posterior capsule opacifi cation, increased intraocular pressure, and anterior chamber infl ammation. Use of OMIDRIA in children has not been established. You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. INDICATIONS AND USAGE OMIDRIA is added to ophthalmic irrigation solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. * Randomized, double-masked trial using a 4-arm factorial design to show that OMIDRIA is superior to either agent alone. Post hoc analysis of pupil diameter < 6mm at any time during the procedure. 2 Reimbursement information is based on Omeros data on fi le. Omeros does not guarantee reimbursement for any particular patient. Contact 1-844-OMEROS1 (1-844-663-7671) for more information about how to submit for OMIDRIA reimbursement. References: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2015. 2. Omeros data on fi le. 3. Department of Health and Human Services. Centers for Medicare and Medicaid Services. MLN Matters. Number MM9014. 2014:1-19. 4. Federal Register, April 7, 2000, 65 FR. 5. Kaiser Family Foundation analysis of the CMS Medicare Current Benefi ciary Survey Cost and Use File, 2010. CONTINUOUS THERAPEUTIC EFFECT THROUGHOUT SURGERY 1 MIOSIS PREVENTION AND POSTOP OCULAR PAIN REDUCTION IN ONE 1 FIRST AND ONLY FDAAPPROVED PRODUCT OF ITS KIND FOR CATARACT SURGERY 1 PROVEN 46 TIMES BETTER THAN INTRACAMERAL PHENYLEPHRINE OR KETOROLAC ALONE 2, * Please see the Full Prescribing Information for OMIDRIA at www.omidria.com/prescribinginformation. OMEROS ® , the OMEROS logo ® , OMIDRIA ® , and the OMIDRIA logo ® are registered trademarks of Omeros Corporation. © Omeros Corporation 2015, all rights reserved. 2015-196. AFTER BUNDLING, POSITIVE EFFECT ON FACILITY FEES 4 NO EFFECT ON PHYSICIAN FEES; PASSTHROUGH PAYMENTS HAVE NO EFFECT ON HEALTHCARE SYSTEM 4 FULLY REIMBURSABLE ACROSS ALL PAYER TYPES 2,4,5 REIMBURSED SEPARATELY FROM BUNDLED PAYMENT UNTIL DECEMBER 31, 2017 3,4

• Cover